Abstract: The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula (I), useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.

Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.

Abstract: The present invention relates to a peptide of Formula I, or a pharmaceutically acceptable salt thereof: X—P??Formula I wherein: P is a DPPIV peptide metabolite of regulatory peptides obtained by cleavage of the two N-terminal amino acids; and X is defined by Formula II: wherein: A is selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C1-C10 heteroalkylene, C2-C10 heteroalkenylene, C2-C10 heteroalkynylene and phenyl; and B is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl and C3-C7 cycloalkyl.

Abstract: The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula: 1

Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

Abstract: This invention relates to compositions for removing biofilms from contaminated surfaces. The compositions minimally comprise a detergent and a salt or a salt-forming acid. Preferably, the compositions comprise a detergent and a salt-forming acid, to provide salts and acids in equilibrium, in such a way that the biofilm is rapidly dismantled and removed in such an environment. The compositions may also comprise a bactericide, for destroying bacteria.

Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:

Abstract: Novel compounds of the formula (I) wherein: one of R1, R2, R3, R4, and (R10)n represents an halogen atom and each of the remaining R1, R2, R3, R4, and each of the remaining R10 group is independently selected in the group constituted by hydrogen, halogen atoms, an amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxy, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamidosulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl group and by the corresponding substituted groups; —m=0-1; n=1-4, A is nil, O, or NH; R9 represents an alkylene group; —Z is H, amino, dialkylamino, or trialkylamino salt; X—is an anion; R5, R6, R7 a

Abstract: The present invention is concerned with modified biological peptides providing increased potency, prolonged activity and/or increased half-life thereof. The modification is made via coupling through an amide bond with at least one conformationally rigid substituent, either at the N-terminal of the peptide, the C-terminal of the peptide, on a free amino or carboxyl group along the peptide chain, or at a plurality of these sites. Those peptides exhibit clinical usefulness for example in treating states of insulin resistance associated with pathologies such as type II diabetes.

Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

Abstract: A beverage brewing apparatus having an automatic brew cycle mode and a semi-automatic brew cycle mode.

Abstract: This invention relates to compositions for removing biofilms from contaminated surfaces. The compositions minimally comprise a detergent and a salt or a salt-forming acid. Preferably, the compositions comprise a detergent and a salt-forming acid, to provide salts and acids in equilibrium, in such a way that the biofilm is rapidly dismantled and removed in such an environment. The compositions may also comprise a bactericide, for destroying bacteria.

Abstract: A beverage brewing apparatus having an automatic brew cycle mode and a semi-automatic brew cycle mode.

Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.

Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

Abstract: Myocardial protection is achieved by administering to a patient an effective amount of a benzothiazepine derivative. The benzothiazepine derivatives have the following general chemical formula: ##STR1## wherein R.sub.1 represents hydrogen or methyl,R.sub.2 represents hydrogen or acetyl,R.sub.3 represents hydrogen or methyl, andR.sub.4 represents hydrogen or a halogen,with the proviso that R.sub.1 cannot be methylwhen R.sub.2 =acetyl, R.sub.3 =methyl and R.sub.4 =hydrogen.The above compounds may also be used in other clinical conditions such as treatment of stable and unstable angina, non-Q-wave myocardial infarction, cerebral trauma ischemia and reperfusion, organ graft preservation, etc.